Table 4 Comparison of clinical characteristics between patients with cyclosporine A-related neurotoxicity and those without
Characteristic | Neurotoxicity | Non-neurotoxicity | P |
|---|---|---|---|
No. of patients | 7 | 44 | Â |
Male gender, n (%) | 5 (72%) | 34 (78%) | 0.662 |
Age at HID-HSCT (years), median (range) | 7 (1.6) | 8 (4.4) | 0.212 |
Underlying disease, n (%) | Â | Â | 0.221 |
 Acute leukemia | 6 (86%) | 38 (87%) |  |
 Myelodysplastic syndrome | 1 (14%) | 1 (2%) |  |
 Aplastic anemia | 0 (0%) | 5 (11%) |  |
State of underlying disease at HSCT, n (%) | Â | Â | 0.685 |
Complete remission | 5 (72%) | 25 (57%) | Â |
Not in remission | 2 (28%) | 19 (43%) | Â |
Hypertension after CSA, n (%) | 5 (71%) | 5 (11%) | 0.002 |
Electrolyte imbalance, n (%) | Â | Â | Â |
 Hyponatremia | 3 (43%) | 7 (16%) | 0.095 |
 Hypokalemia | 6 (86%) | 33 (75%) | 0.223 |
 Hypocalcemia | 5 (71%) | 18 (41%) | 0.221 |
 Hypomagnesemia | 2 (29%) | 10 (23%) | 0.662 |
Maximum trough CSA level > 250 ng/mL, n (%) | 3 (43%) | 12 (27%) | 0.406 |
ABO blood type of donor and recipient, n (%) | Â | Â | 0.427 |
 Matched | 3 (43%) | 27 (61%) |  |
 Mismatched | 4 (57%) | 17 (39%) |  |
Gender of donor and recipient, n (%) | Â | Â | 0.923 |
 Matched | 3 (43%) | 18 (41%) |  |
 Mismatched | 4 (57%) | 26 (59%) |  |
Acute GvHD, n (%) | Â | Â | 0.300 |
 Yes | 5 (72%) | 38 (86%) |  |
 No | 2 (28%) | 6 (14%) |  |